Japanese drugmaker Mochida Pharmaceutical (TYO: 4534) announced that Thien Thao Pharmaceutical Joint Stock Company, a partner of Meiji, has obtained approval to import and market Epadel S, a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan, for the treatment of hypertriglyceridemia in Vietnam.
Mochida has granted Meiji the exclusive rights to develop and market Epadel S in Vietnam, and Meiji has proceeded to obtain approval to import and market Epadel S by Thien Thao. Since this approval, Mochida will supply Epadel S to the Vietnamese market, and Meiji will exclusively sell Epadel S in Vietnam through Thien Thao.
Additionally, Mochida will provide support to Thien Thao through Meiji. Mochida and Meiji have entered into a contract for the sale of Epadel S in the ASEAN region, including Vietnam, as well as in China and Taiwan. As of today, Epadel S has been sold in Thailand. Going forward, Mochida and Meiji will contribute to improving the quality of life of patients by providing Epadel S in Vietnam as well.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze